- Frenetic search for survivors as 91 feared dead in tornado-hit Oklahoma |
- Israel fires back at Syria after gunshots at its troops
- Drop in U.S. underground water levels has accelerated -USGS
- Dollar firms as Fed suspense builds, shares off highs |
- IRS officials back on Capitol Hill hot seat over targeting
Storm chasers brave danger and debris as they try to capture photos of tornadoes' destructive power. Slideshow
MediciNova asthma drug fails trial; shares crash
(Reuters) - Biopharmaceutical company MediciNova Inc said its experimental asthma drug failed to meet the main goal of a second mid-stage trial, sending its shares down as much as 51 percent in extended trade.
MediciNova, which is testing MN-221 as a treatment for acute asthma attacks not responsive to standard therapy, said the drug showed no improvement when compared with a placebo.
MN-221 looks to treat the condition by bypassing constricted airways to deliver the drug directly into the lungs. It aims to improve FEV1 ratio when compared with a placebo.
FEV1 ratio measures volume of air exhaled in the first second.
The trial, however, demonstrated a reduction in hospital admissions when MN-221 was added to standard treatments, the company said in a statement.
MediciNova, which said there were three serious adverse events in the trial, plans to continue development of the drug.
Shares in the San Diego, California-based company fell 51 percent to $1.35 in extended trade. They closed at $2.75 on Wednesday on the Nasdaq.
(Reporting by Balaji Sridharan in Bangalore; Editing by Sriraj Kalluvila)
- Tweet this
- Share this
- Digg this